Skip to main content

Top 6 Practice-Changing Highlights from ACR26

Janet.Pope@sjhc.london.on.ca
Nov 16, 2026 8:00 am

The content at ACR Orlando was vast. I looked at several posters/listened to many talks and heard from colleagues. So if I missed some great abstracts that will be practice changing for you, I apologize in advance.

Here is my list TOP 6 practice changing themes:

6. H2H of Bimekizumab vs Risankizumab for PsA

Winner is….Bimekizumab (BE BOLD) 49.1% versus 38.0% ACR50
(not sure which to choose if skin is bad)
Abstract 2804

5. Gout +RCT

Urate lowering #URAT1i +RCT Pozdeutinurad – not sure of safety in CKD and not all pts had failed allopurinol or febuxostat
Don’t know where it will fit as
LB20

4. RCT in inflammatory myositis (dermatomyositis + immune mediated necrotizing myopathy)

FcRN Efgartigimod 
Truly + on endpoints and subsets both favored active Rx, pts on background IS stable doses
CK improved and muscle power
Some hypogammaglobulinemia in this class of meds
LB24

3. 2+RCTs in SjD

Dazzled by Dazodalibep (CD40Li)
LB22
Or should I choose Ianalumab – LTE presented LB14
(one neg FcRn RCT w Efgartigimod – RCT stopped Oct 2026)

2. SLE +RCTs

Dapirolizumab pegol (CD40Li) -LLDAS -Phase 3 RCT already published
Abstract 2916

Obinutuzimab (CD20 deep depleter) for LN and nonrenal SLE – both RCTs published
Abstract 2217 Improvements of components of SLEDAI

Litifilimab in cutaneous features with cross over PBO to active and sustained benefit at 1 yr on active Rx – new MOA inhibits dendritic cells
Abstract 0872

Afimetoran + RCT with once daily oral TLR7/8 inhibitor
Many high bar outcomes
LB23

1.Big winner is a loser…(of BMI that is excessive)

Retatrutide Phase 3 results for retatrutide (sc weekly) Once-weekly retatrutide (doses including 4 mg, 9 mg, or 12 mg
Retatrutide is a drug with 3 components:  GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and Glucagon
Presentations were from the TRIUMPH-4 and TRIUMPH-1-OA studies(80 weeks)
Retatrutide reduced knee pain on WOMAC Pain subscale (reductions of approximately –3.66 to –4.30 points across retatrutide doses vs. –2.24 with placebo, p < 0.001)
Change body weight ranged from ‑18.6% to -28.7%!

Abstract 2573 | Abstract 0871

This will change my practice, when this is available. The BIG question that ‘weighs’ on me, is it all due to weight loss or is it combined with anti-inflammatory properties that improve OA symptoms. The other question is – are the weight loss hormonal drugs DMOADs (disease modifying). 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×